Literature DB >> 7507156

Membrane defence against complement lysis: the structure and biological properties of CD59.

A Davies1, P J Lachmann.   

Abstract

The complement system is an important branch of the innate immune response, constituting a first line of defence against invading microorganisms which activate complement via both antibody-dependent and -independent mechanisms. Activation of complement leads to (a) a direct attack upon the activating cell surface by assembly of the pore-forming membrane attack complex (MAC), and (b) the generation of inflammatory mediators which target and recruit other branches of the immune system. However, uncontrolled complement activation can lead to widespread tissue damage in the host, since certain of the activation products, notably the fragment C3b and the C5b-7 complex, can bind nonspecifically to any nearby cell membranes. Therefore it is important that complement activation is tightly regulated. Our own cells express a number of membrane-bound control proteins which limit complement activation at the cell surface and prevent accidental complement-mediated damage. These include decay-accelerating factor, complement receptor 1 and membrane cofactor protein, all of which are active at the level of C3/C5 convertase formation. Until recently, cell surface control of MAC assembly had been attributed to a single 65-kD membrane protein called homologous restriction factor (alternatively named C8-binding protein and MAC-inhibiting protein). However a second MAC-inhibiting protein has since been discovered and it is now clear that this protein plays a major role in the control of membrane attack. This review charts the rapid progress made in elucidating the protein and gene structure, and the mechanism of action of this most recently discovered complement inhibitor, CD59.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507156     DOI: 10.1007/bf02918257

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  132 in total

1.  Cytoprotective effect of CD59 antigen on xenotransplantation immunity.

Authors:  T Akami; R Sawada; N Minato; M Naruto; A Yamada; J Imanishi; M Mitsuo; I Nakai; M Okamoto; H Nakajima
Journal:  Transplant Proc       Date:  1992-04       Impact factor: 1.066

2.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.

Authors:  I Stefanová; I Hilgert; H Kristofová; R Brown; M G Low; V Horejsí
Journal:  Mol Immunol       Date:  1989-02       Impact factor: 4.407

3.  Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.

Authors:  D J Carothers; S V Hazra; S W Andreson; M E Medof
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and serum phospholipase D.

Authors:  J P Toutant; W L Roberts; N R Murray; T L Rosenberry
Journal:  Eur J Biochem       Date:  1989-04-01

5.  The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases.

Authors:  T Cinek; V Horejsí
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

6.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

Authors:  S Schönermark; E W Rauterberg; M L Shin; S Löke; D Roelcke; G M Hänsch
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

7.  Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  E Ueda; J Nishimura; T Kitani; K Nasu; T Kageyama; Y U Kim; J Takeda; T Kinoshita
Journal:  Int Immunol       Date:  1992-11       Impact factor: 4.823

8.  Glycophorin A inhibits lysis by the complement attack phase.

Authors:  H Brauch; D Roelcke; U Rother
Journal:  Immunobiology       Date:  1983-08       Impact factor: 3.144

9.  Colocalization of the human CD59 gene to 11p13 with the MIC11 cell surface antigen.

Authors:  W A Bickmore; D Longbottom; K Oghene; J M Fletcher; V van Heyningen
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

10.  Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  53 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Monocyte-bound monoclonal antibodies inhibit the Fc gamma RI-mediated phagocytosis of sensitized red cells: the efficiency and mechanism of inhibition are determined by the nature of the antigen.

Authors:  S L Shepard; A G Hadley
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

4.  Apicomplexan perforin-like proteins.

Authors:  Björn F C Kafsack; Vern B Carruthers
Journal:  Commun Integr Biol       Date:  2010-01

5.  Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract.

Authors:  A E Berstad; P Brandtzaeg
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 6.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice.

Authors:  M T Birke; E Lipo; M Adhi; K Birke; R Kumar-Singh
Journal:  Gene Ther       Date:  2014-03-27       Impact factor: 5.250

8.  Plasma Glycated CD59 Predicts Early Gestational Diabetes and Large for Gestational Age Newborns.

Authors:  DongDong Ma; Miguel Angel Luque-Fernandez; Delia Bogdanet; Gernot Desoye; Fidelma Dunne; Jose A Halperin
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

9.  Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.

Authors:  K J Marchbank; B P Morgan; C W van den Berg
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.